ASH 2018 | AMG 420 BiTE for R/R multiple myeloma
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
The AMG 420 bi-specific T-cell engager (BiTE) therapy which targets the anti–B-cell maturation antigen (BCMA) is now being tested in relapsed/refractory multiple myeloma (MM). Here, Thierry Facon, MD, of Lille University Hospital, Lille, France, also discusses the latest data from the Phase I dose-escalation study (NCT02514239) assessing the safety, tolerability and anti‑tumor activity of AMG 420, a CD3 BiTE. Dr Facon presented the data at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA,
Get great new content delivered to your inboxSign up